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Abstract
Background: We newly proposed that “Furuta method,” a pharmacist intervention guidelines, is a topical ointment
therapy that considers the physical properties and moist environment of wounds for pressure ulcer (PU) treatment.
The aim of this multicenter retrospective study was to investigate the effectiveness of this method for PU.
Methods: A total of 888 consecutive patients who underwent treatment for PU at 37 hospitals and five dispensing
pharmacies in Japan between August 2010 and July 2014 were included in the study. Based on a survey on compliance
to “Furuta method,” single-blind allocation was conducted into compliance (n = 437) and non-compliance (n = 451)
groups, followed by a retrospective data collection. The primary and secondary outcomes were the healing period and
rates of unhealed wounds, respectively. Data was expressed as mean ± standard deviation. Two-sided log rank
tests were used for between-group comparisons of PU progression, whereas Kaplan–Meier plots were used for
comparison between groups. We performed rigorous adjustment for marked differences in baseline patient
characteristics by propensity score (PS) matching.
Results: After PS matching, patients were categorized as DESIGN-R d2 (n = 202), D3 (n = 130), D4 and 5 (n = 76),
and DU (n = 76). In terms of the healing period, the patients in the compliance groups healed faster than those
in the non-compliance groups in d2 (23.6 ± 36.8 vs. 32.2 ± 16.6 days; P < 0.001), D3 (46.8 ± 245.5 vs.137.3 ± 52.7 days;
P < 0.001), and D4, 5 (122.5 ± 225.7 vs. 258.2 ± 292.7 days; P < 0.001). There were significantly lesser events of PU
progression in the compliance group than in the non-compliance group (15 vs. 54; P = 0.003).
Conclusions: “Furuta method” is the new therapeutic strategy of PU, a pharmacist intervention guidelines, may
possibly increase healing rates of PUs.
Keywords: Pressure ulcer, Wound physical property, Wound fixation, Furuta method
Background
Pressure ulcers (PUs) may develop when persistent pres-
sure on bony prominences obstructs a healthy capillary
flow, leading to tissue necrosis [1]. The primary cause of
PUs is ischemic changes induced by pressure-related
external forces, including shear force [2], and it is a
common complication of immobility among the elderly
[3]. Moreover, the elderly are at a high risk of developing
PU because of immobility [4, 5], poor nutritional status
[6, 7], and decreased body weight [5]. Despite recent re-
search developments in the process of wound healing,
treatment strategies for pressure ulcers remain inconclu-
sive [8]. PU is a major contributor to an impaired quality
of life by increasing mortality and the length of stay,
burdening healthcare systems [9, 10].
An important factor in treatment resistance is the
undermining formation, commonly observed in deep
PUs [11]. Treatment-resistant PUs may be associated
with changes in physical wound properties because of
aging, such as mobility and deformity [12], and the high
incidence of the undermining formation in PUs over the
sacrum, coccyx, and greater trochanter [13]. Evaluation
of wound deformity and mobility has been shown to
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improve healing following topical ointment therapy [14];
moreover, an active control of topical ointment applica-
tion has been demonstrated to be important for moist
wound healing in PUs [15].
In Japan, PUs have been treated by a team comprising
physicians, pharmacists, and nurses, based on physical
properties of the wound and using topical ointment for
moist wound healing. Thus, this concept has been
shown to be therapeutically effective at an improved
medical cost [16]. Further, it has been spreading to phar-
macists in Japan. However, there have been no detailed
descriptions of interventions by pharmacists for PU
treatment. Based on this background, we newly pro-
posed the concept of topical ointment therapy by phar-
macists, called “Furuta method” (Appendix), for PU,
considering the physical properties and moist environ-
ment of wounds, and we promote widespread training
sessions according to Furuta method in Japan. The aim
of this study was to investigate the effectiveness of PU
therapeutic effects treated by trained pharmacist accord-
ing to “Furuta method” in Japan and to compare the re-




The study was based on compliance surveys and retro-
spective data collection from 37 hospitals and five
dispensing pharmacies in Japan. Hospitals and dispens-
ing pharmacies were appealed to participate via the
“decunet” mailing list used by pharmacists involved in
PU. Pharmacists who participated in this study under-
went training sessions according to “Furuta method” in
Japan. We set the suitable standards for the PU team,
which comprised physicians, pharmacists, nurses, and
other medical staff. Data of the National Center for
Geriatrics and Gerontology (NCGG) were excluded be-
cause Furuta was involved in PU treatment. Finally, 35
hospitals and four pharmacies were included. All re-
searchers collected data in a severely managed the per-
sonal information. The study protocol was approved by
the ethics committee of NCGG.
Compliance survey
For compliance confirmation of pharmacist intervention
guidelines on PU topical ointment therapy called “Furuta
methods” (see Appendix), a self-administered 10-item
questionnaire including the questions was provided:
1. are you treating PU more than once a week?; 2. do
you assess the wound using descriptive ulcer dermatology?;
3. do you assess ointment base properties?; 4. do you assess
wound surface moisture and use the Expert Furuta Blend
ointment?; 5. do you assess the physical properties of the
wound?; 6. do you treat the wound using wound fixation?;
7. do you assess the wound surface and edge?; 8. do you
control the moisture of the wound by assessing granulation
tissue deformation by an external force?; 9. do you assess
external forces applied to the wound and treat by wound
fixation?; and 10. do you assess residual tissue, such as the
dermis, subcutaneous tissue, and fascia? This questionnaire
was completed by responding yes (1 point) or no (0 point).
This questionnaire was a single-blind method, which allo-
cated patients to the compliance (≥8 points) and non-
compliance (<8 points) groups. This was followed by a
retrospective data collection.
Patients
A total of 888 consecutive patients who underwent PU
treatment in Japan between August 2010 and July 2014
were enrolled in this study (Fig. 1). Only patients who
met the following criteria were included: (a) patients
whose diagnosis were assigned as DESIGN-R [17] ≥ d2;
(b) patients who received intervention from the PU team
for ≥7 days during the observational period. Patient with
missing information on the following data were excluded
from this study: age, sex, hemoglobin, serum albumin, site
of PU, DESIGN-R score, and observation period. Thus, a
total of 868 patients were included; the mean patient age
was 80.0 ± 11.3 years (standard deviation, Table 1).
Propensity score matching
To reduce treatment-selection bias and potential con-
founding variables, we performed rigorous adjustment
for marked differences in baseline patient characteristics
with propensity score (PS) matching using the following
algorithm: 1:1 optimal match with a ±0.03 caliper and no
replacement. Possible confounders were selected based on
clinical knowledge for their potential association with the
outcome of interest. The PS model was estimated using a
logistic regression model that adjusted for patient charac-
teristics, such as age, sex, hemoglobin, albumin, DESIGN-
R score at baseline, and observation period. To measure
covariate balance, an absolute standardized difference
above 10 % represented meaningful imbalance [18, 19].
Study variables and statistical analysis
The main outcome was a comparison of healing days,
which was calculated based on a previous study [20] that
used the following equation:
Treatment period ¼ DESIGN‐R score at baseline
Healing rate
Healing rate ¼ DESIGN‐R score at baselineð Þ
‐ DESIGN‐R score at endpointð Þ
 Intervened periodð Þ
DESIGN-R was used for monitoring of PU healing
progression and is defined by the following components:
Furuta et al. Journal of Pharmaceutical Health Care and Sciences  (2015) 1:21 Page 2 of 9
depth, exudate, size, inflammation/infection, granulation
tissue, necrotic tissue, and pocket [17]. The secondary
endpoint was rates of unhealed wound.
Data were presented as mean ± standard deviation.
Paired comparisons were performed using paired t-test
for categorical variables and Mann–Whitney U test for
continuous variables. Kaplan–Meier plots were created
for evaluating the study endpoints, and the respective
95 % CI values were calculated. For the Kaplan–Meier plot
for PU progression, all patients were included except for
healed cases. Moreover, two-sided log rank tests were used
for between-group comparisons of PU progression. All
analyses were performed using SPSS version 22.0 software
(SPSS Inc, Chicago, IL, USA). A two-tailed P value
of <0.05 was considered statistically significant.
Results
The mean compliance survey point was 7.3 ± 2.8, and
results were collected from 19 (437 patients) and 20
(451 patients) facilities. In the questions 2, the com-
pliance rate based on descriptive ulcer dermatology
was the lowest.
Based on the DESIGN-R criteria, 343 patients were di-
agnosed as d2, 220 as D3, 159 as D4, 5, and 146 patients
as DU (Table 1). Individuals who did and did not
undergo treatment based on “Furuta method” differed
for all measured characteristics.
Table 2 shows the detailed characteristics of patients
included in the final analysis: d2 (n = 202); D3 (n = 130);
D4, 5 (n = 76); and DU (n = 76). The covariate bal-
ance in the matched cohort considerably improved.
In Fig. 2, for each DESIGN-R group of patients, the
respective duration of healing was significantly shorter
in the compliance group than in the non-compliance
group: d2 (23.6 ± 36.8 vs. 32.2 ± 16.6 days; P < 0.001); D3
(46.8 ± 245.5 vs. 137.3 ± 52.7 days; P < 0.001); D4, 5
(122.5 ± 225.7 vs. 258.2 ± 92.7 days; P < 0.001); and DU
(78.1 ± 298.9 vs. 142.5 ± 79.4 days; P < 0.001). Moreover,
Fig. 1 Flow chart for study group inclusion. Patients were grouped according to the DESIGN-R category of depth and were divided into two
groups based on compliance survey results. Finally, patients were allocated by propensity score matching
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Age (years) 82.4 ± 9.0 79.3 ± 11.6 29.9 0.06 81.1 ± 10.3 78.8 ± 12.9 19.7 0.137
Sex (male) (%) 51.9 54.5 3.8 0.403 56.0 55.6 0.6 0.949
Hemoglobin (g/dL) 10.9 ± 2.2 10.8 ± 2.3 4.4 0.529 10.5 ± 2.1 10.7 ± 1.9 10.0 0.57
Albumin (g/dL) 2.9 ± 0.6 2.9 ± 0.8 0.0 0.808 2.6 ± 0.6 2.6 ± 0.6 0 0.38
DESIGN-R score at baseline 9.4 ± 4.9 7.5 ± 4.8 39.1 <0.001 15.4 ± 7.3 15.4 ± 7.0 0 0.969
Observational period (day) 23.1 ± 20.1 26.1 ± 23.8 13.6 0.211 43.2 ± 42.1 57.3 ± 93.1 19.5 0.132
Locations - -
Sacrum 55 87 - - 43 38 - -
Coccyx 22 20 - - 7 9 - -
Greater trochanter 17 13 - - 20 8 - -
Heel 10 17 - - 24 10 - -
Ilium 4 7 - - 5 4 - -















Age (years) 80.5 ± 11.5 80.5 ± 10.8 0 0.988 79.2 ± 10.0 76.7 ± 14.7 19.9 0.265
Sex (male) (%) 40.3 36.3 5.1 0.624 45.7 56.3 15.1 0.213
Hemoglobin (g/dL) 9.9 ± 1.8 10.1 ± 1.7 11.4 0.606 9.9 ± 1.9 10.5 ± 2.1 29.9 0.107
Albumin (g/dL) 2.6 ± 0.6 2.5 ± 0.7 15.3 0.727 2.6 ± 0.5 2.7 ± 0.6 18.1 0.25
DESIGN-R score at baseline 28.0 ± 12.5 23.0 ± 7.3 48.9 0.007 24.6 ± 10.3 20.3 ± 10.3 41.7 0.014
Observational period (day) 70.5 ± 55.6 68.8 ± 65.5 2.7 0.86 52.5 ± 59.7 57.3 ± 88.8 6.3 0.718
Locations - -
Sacrum 56 28 - - 16 32 - -
Coccyx 3 2 - - 2 3 - -
Greater trochanter 8 4 - - 7 13 - -
Heel 11 4 - - 14 20 - -
Ilium 4 5 - - 5 3 - -





























Age (years) 81.9 ± 8.5 82.4 ± 8.2 5.9 82.4 ± 8.6 81.8 ± 10.8 6.1
Sex (male) (%) 53.4 55.4 4.4 52.3 49.2 4.4
Hemoglobin (g/dL) 10.7 ± 2.1 10.9 ± 2.0 9.8 10.3 ± 1.9 10.4 ± 1.7 5.5
Albumin (g/dL) 2.9 ± 0.6 2.9 ± 0.6 0 2.6 ± 0.5 2.6 ± 0.6 0
DESIGN-R score at baseline 8.6 ± 4.4 8.2 ± 4.5 8.9 14.7 ± 7.7 15.1 ± 6.5 5.6
Observational period (day) 23.9 ± 21.1 22.6 ± 21.5 6.1 46.6 ± 53.4 42.1 ± 38.5 9.6
Locations
Sacrum 39 47 23 26 -
Coccyx 14 7 - 5 4 -
Greater trochanter 7 8 - 7 4 -
Heel 9 12 - 11 7 -
Ilium 3 6 - 3 5 -














Age (years) 80.8 ± 12.0 80.3 ± 11.9 4.2 78.2 ± 11.0 77.6 ± 14.3 4.7
Sex (male) (%) 31.6 39.5 9.8 47.4 47.4 0
Hemoglobin (g/dL) 10.2 ± 2.1 10.3 ± 1.5 5.5 10.1 ± 2.0 10.3 ± 1.8 5.3
Albumin (g/dL) 2.6 ± 0.7 2.6 ± 0.7 0 2.6 ± 0.6 2.6 ± 0.6 9.8
DESIGN-R score at baseline 25.9 ± 11.4 25.0 ± 9.8 8.5 21.5 ± 8.4 22.1 ± 7.0 7.8
Observational period (day) 66.3 ± 47.2 63.3 ± 45.8 7.1 49.0 ± 61.5 45.1 ± 42.3 7.4
Locations
Sacrum 20 22 - 11 15 -
Coccyx 1 3 - 2 2 -
Greater trochanter 2 1 - 8 4 -
Heel 3 1 - 7 10 -
Ilium 1 2 - 2 2 -















wound healing was significantly different among the
DESIGN-R groups (P < 0.001, data not shown).
Figure 3 shows the Kaplan–Meier plot for PU progres-
sion, according to the DESIGN-R score. The number of
cases with PU progression was significantly lesser in the
compliance group (n = 92) than in the non-compliance
group (n =157) (15 vs. 54, respectively; P = 0.003; Fig. 3).
Discussion
The results of our study demonstrate that “Furuta
method,” was effective for PU treatment in terms of
early complete recovery and prevention of PU progres-
sion. However, there is a need for aggressive pharmacist
intervention while using this method. It is important to
conduct simultaneous prevention and treatment for PU;
in this study, it is noteworthy that the compliance group
did not deteriorate. Pharmacists who participated in this
study, result of trained workshop according to Furuta
methods, more improved assessment of topical ointment
therapy considering the external force for PUs were
compared with similar factors in the non-compliance
group.
In a previous report conducted at NCGG, treatment
periods according to National Pressure Ulcer Advisory
Panel (NPUAP) stage definitions were 10 ± 6 days for
Stage II, 43 ± 17 days for Stage III, and 80 ± 32 days for
Stage IV [20]. In our study, the mean duration of healing
in the compliance group was 23.6 ± 36.8 days in pa-
tients with d2, 46.8 ± 245.5 days in patients with D3,
and 122.5 ± 225.7 days in patients with D4 and D5.
In a previous study, only NCGG data (based on “Furuta
method”), encompassed a wide range of treatment periods
that was comparable with the present study. We believe
the low compliance observed with “Furuta method” may
be influenced by the treatment period. Further, the com-
pliance rate with descriptive ulcer dermatology was the
lowest, and this pathological assessment was not routinely
performed by general healthcare workers. It is necessary
to educate pharmacists and general healthcare workers re-
garding these techniques. A randomized single-blind con-
trolled trial reported 8-week healing rates for Stage II
ulcers of only 50 % in both groups [21]. Moreover, Horn
et al. reported treatment failure rates for Stage III and IV
ulcers of 90 % at 8 weeks [22]. These reports mainly inves-
tigated dressing therapy for PU and did not evaluate
wound assessment according to wound physical properties
and descriptive ulcer dermatology. It has been proposed
that topical ointment therapy according to Furuta
methods had a greater efficacy than dressing therapy.
Furthermore, in this study, there were significantly
fewer cases of PU progression in the compliance group
than in the non-compliance group (15 vs. 54; P = 0.003).
Thus, we believe that an appropriate wound assessment
according to “Furuta method” has utility in preventative
management.
This study has several limitations. First, it is a retro-
spective, albeit multicenter, study; hence, there is a po-
tential for bias. This was minimized by performing PS
Fig. 2 Treatment period for pressure ulcers according to DESIGN-R category of depth. The two groups in each DESIGN-R score was compared
using Mann–Whitney U test
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matching, which has been previously shown to be useful
[23]. Second, this study did not consider the involve-
ment of the nutritionist and physical therapist. There-
fore, prospective trials that consider these other factors
are necessary in the future.
Conclusion
We introduce a concept of PU topical ointment therapy,
called “Furuta method,” which considers the physical
properties and moist environment of wounds and
pharmacist intervention guidelines and may be aided by
pharmacist participation. This method may possibly lead
to an increase in PU healing rates.
Appendix
Pharmacist intervention guidelines on pressure ulcer
topical ointment therapy “Furuta method”
Wound assessment
It is desirable to examine the wound at least once a week
based on descriptive ulcer dermatology [24].
1) Wound physical property [12]: Assess by wound
mobility and deformity. Wound mobility is the
movement of the wound from the bony prominence,
whereas wound deformity is a change in the three-
dimensional shape of the wound and can result in
undermining formation, a characteristic of deep
pressure ulcers. Layered granulation tissue arising
from wound deformity attenuates topical ointment
therapy.
2) Wound fixation [25]: Wound fixation is defined as
alleviation of wound deformity by exogenous
materials. It is classified as traction, anchor, and
insertion. Wound fixation by traction is performed
using an elastic bandage. Wound fixation by anchor
also alleviates direct pressure on the wound using
sponge (Reston™, Sumitomo 3 M, Tokyo, Japan
or Prosoft™, NICHIBAN, Tokyo, Japan). Wound
fixation by insertion is usually performed using
materials of an appropriate hardness and
absorbability, such as chitin cotton and alginate
foam. For each case, the external force of the
pressure ulcer was evaluated in order to select
the appropriate wound fixation method.
3) Residual tissue [24]: To evaluate and eliminate
necrosis in residual tissue, such as the dermis,
subcutaneous tissue, and fascia. However, physical
properties of the wound are stabilized in the
dermis.
4) Wound surface and edge: To evaluate the several
properties of the wound surface and edge, such as
edematous, sclerotic, dry, glossy, or hemorrhagic
granulation tissue; flat with smooth edge sunken
with smooth edge or sunken with indented edge;
Fig. 3 Progression of pressure ulcer. Kaplan–Meier estimates for the progression of pressure ulcer. There were 15 events of progression in the
compliance group (n = 92) and 54 events of progression in the non-compliance group (n = 157; P = 0.003). *The two groups were compared by
log rank test
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and fibrin-coated film. Based on the evaluation of
the wound surface and edge, the moisture of the
wound was controlled by the characteristics of the
ointment base (active or passive absorption) [26].
5) Granulation tissue: The granulation tissue is
deformed by an external force. Edematous
granulation tissue formation by an external force is
necessary to consider the measures of preventing the
cause of the external force. Based on the evaluation
of the granulation tissue, the moisture of the wound
was controlled using characteristics of the ointment
base (active or passive absorption) [26], and the
external force was controlled by wound fixation [25].
6) Pocket: A wound pocket is mainly formed by an
external force. Based on the evaluation of the external
force on the pocket, the moisture of the wound was
controlled using characteristics of the ointment base
(active or passive absorption) [26], and the external
force was controlled by wound fixation [25].
Topical agent assessment
The selection of a topical ointment was based on the
“Japanese society of pressure ulcers Guidelines for the
Prevention and Management of Pressure Ulcers” [27].
As necessary, wound assessment based on descriptive ulcer
dermatology [24] considered the use of Expert Furuta
Blend Ointment [28]. Exudate formation in the wound was
confirmed by checking the top dressing and gauze.
1) Shallow pressure ulcer
1. Inflammation and infection: Povidone–iodine
sugar ointment, dextranomer beads, cadexomer
iodine beads, iodine–potassium iodide gel, and
iodoform gauze
2. Necrotic tissue
Under the wound surface moisture: silver sulfadiazine
cream, and iodoform gauze with saline
Over the wound surface moisture: iodoform gauze and
bromelain ointment
3. Epithelialization
Under the wound surface moisture: lysozyme
hydrochloride ointment with sulfadiazine ointment (3:7),
bucladesine sodium ointment, alprostadil alfadex ointment,
trafermin splay, lysozyme hydrochloride ointment with
iodine gel (1:1), and hydrocolloid dressing
Over the wound surface moisture: povidone–iodine
sugar ointment and urethane foam dressing
2) Deep pressure ulcer
1) Inflammation and infection: povidone–iodine
sugar ointment, dextranomer beads, cadexomer
iodine beads, iodine–potassium iodide gel, and
iodoform gauze
2. Necrotic tissue
Surgical debridement for black necrotic tissue
Under the wound surface moisture: silver sulfadiazine
cream and iodoform gauze with saline.
Over the wound surface moisture: iodoform gauze,
bromelain ointment, povidone–iodine sugar ointment,
dextranomer beads, cadexomer iodine beads, and iodine–
potassium iodide gel
3) Formation of granulation tissue
Edematous granulation tissue: povidone–iodine sugar
ointment, povidone–iodine sugar ointment with dextra-
nomer beads (4:1), and tretinoin tocoferil ointment with
dextranomer beads (3:2)
Dry granulation tissue: tretinoin tocoferil ointment,
trafermin spray, povidone–iodine sugar ointment with
tretinoin tocoferil ointment (3:1), tretinoin tocoferil
ointment with sulfadiazine ointment (3:7), and tretinoin
tocoferil ointment with dextranomer beads (3:2)
4) Epithelialization
Under wound surface moisture: lysozyme hydrochloride
ointment with sulfadiazine ointment (3:7), bucladesine
sodium ointment, alprostadil alfadex ointment, trafermin
spray, lysozyme hydrochloride ointment with iodine
gel (1:1), and hydrocolloid dressing
Over the wound surface moisture: povidone–iodine
sugar ointment, and urethane foam dressing
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